175 related articles for article (PubMed ID: 15773288)
1. Hatch-Waxman in the Federal Courts: from 1994--2004.
Ludwig SP; Kosinski KB; Harris J
Drug Dev Ind Pharm; 2005 Jan; 31(2):215-22. PubMed ID: 15773288
[TBL] [Abstract][Full Text] [Related]
2. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
3. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
4. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
[TBL] [Abstract][Full Text] [Related]
5. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
Hui YF
Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
[TBL] [Abstract][Full Text] [Related]
6. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
7. How drug life-cycle management patent strategies may impact formulary management.
Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
[TBL] [Abstract][Full Text] [Related]
8. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
9. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
10. Teva v. Eisai: what's the real "controversy"?
Wang GL
Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
[TBL] [Abstract][Full Text] [Related]
11. The Hatch-Waxman Act: encouraging innovation and generic drug competition.
Sokal AM; Gerstenblith BA
Curr Top Med Chem; 2010; 10(18):1950-9. PubMed ID: 20615183
[TBL] [Abstract][Full Text] [Related]
12. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
Eccleston LE
Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
[No Abstract] [Full Text] [Related]
13. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
14. Epo, by any other name.
Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170
[No Abstract] [Full Text] [Related]
15. FDA: approval of generic drug reversed by U.S. Court of Appeals.
Beliveau S
J Law Med Ethics; 2002; 30(1):120-2. PubMed ID: 11905262
[No Abstract] [Full Text] [Related]
16. Delayed access to generic medicine: a comment on the Hatch-Waxman Act and the "approval bottleneck".
Patel AN
Fordham Law Rev; 2009 Nov; 78(2):1075-115. PubMed ID: 19938382
[TBL] [Abstract][Full Text] [Related]
17. A new history and discussion of 180-day exclusivity.
Korn DE; Lietzan E; Scott SW
Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
[TBL] [Abstract][Full Text] [Related]
18. The History and Political Economy of the Hatch-Waxman Amendments.
Lietzan E
Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
[No Abstract] [Full Text] [Related]
19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
20. Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S. law and observations for the future.
Engelberg AB
Spec Law Dig Health Care Law; 2000 Sep; (258):9-48. PubMed ID: 11184791
[No Abstract] [Full Text] [Related]
[Next] [New Search]
